Martinsried/Munich, March 15, 2013. Medigene AG (MDG, Frankfurt, Prime Standard) announces that its drug Veregen® has obtained market approval in the Czech Republic. Medigene's marketing partner Nordic Pharma is planning to launch Veregen® in the Czech Republic, Poland, Hungary, and Slovakia during 2013, upon conclusion of the reimbursable price-fixing procedure by the responsible authority.
Veregen® is already being marketed in the USA, Germany, Switzerland, Austria, and Spain by the sales partners Fougera, Abbott, and Bial. Market approvals and the launch in additional countries are pending in 2013. Medigene has entered into several marketing partnerships for Veregen® across Europe, Asia, and America, and is planning to continue this global licensing strategy to further exploit the product's market potential.
About Veregen®: Veregen®, an ointment used in the topical treatment of external genital warts, contains a catechin concentrate based on a defined extract obtained from green tea leaves. Since 2010, Veregen® (Sinecatechins 15% ointment) has been recommended in the US Department of Health and Human Services Center for Disease Control and Prevention's Sexually Transmitted Diseases Treatment Guidelines as a possible option for treating genital warts. Sinecatechins 10% & 15% ointment (Veregen®) was recently also included in the European Guideline for the Management of Anogenital Warts.
Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene was the first German biotech company to have revenues from marketed products, which are distributed by partner companies. It has two drug candidates in clinical trials, EndoTAG®-1 and RhuDex®, and is developing an innovative vaccine technology. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please go to www.medigene.com/unsubscribe.